Hengrui Pharma: H1 2026 Net Profit Reaches RMB 4.465 Billion, a Year-on-Year Increase of 0.34%
In the first half of 2026, Hengrui Pharma reported revenue of RMB 15.456 billion, a year-on-year decrease of 1.94%; net profit amounted to RMB 4.465 billion, a year-on-year increase of 0.34%. The company plans to conduct a share repurchase worth RMB 1 billion to RMB 2 billion, with a repurchase price not exceeding RMB 81.78 per share
Hengrui Pharma announced that its operating revenue for the first half of 2026 was RMB 15.456 billion, a year-on-year decrease of 1.94%. The net profit attributable to shareholders of the listed company was RMB 4.465 billion, a year-on-year increase of 0.34%. The company plans to repurchase shares with a total value between RMB 1 billion and RMB 2 billion, at a price not exceeding RMB 81.78 per share.
Risk Warning and Disclaimer
The market involves risks, and investment should be approached with caution. This article does not constitute personal investment advice, nor does it take into account the specific investment objectives, financial status, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their specific circumstances. Investors bear full responsibility for their own investment decisions.
